Stiff-Person Vereinigung Deutschland - Hilfe für SPS-Kranke  Titel
STIFF–PERSON VEREINIGUNG DEUTSCHLAND E.V. ⊃⊂ 52372 Kreuzau-Stockheim, Raiffeisenstraße 50 ⊃⊂ Tel. 02421 504357

Literatur zum Thema 'Stiff-Person-Syndrom
Quelle: El-Abassi, Rima, et al.: SPS: Understanding the complexity. In: Journal of the Neurological Sciences 404 (2019) 137–149

Weitere Literatur ist → hier zu finden.

0]

Justin Ralph Abbatemarco, et al., Case series: intrathecal baclofen therapy in stiff-person syndrome, Neuromodulation 21 (2018) 655–659.

1]

Said Albahra, et al., Role of plasma exchange in stiff person syndrome, Transfus. Apher. Sci. 58 (3) (2019) 310–312.

2]

R.A. Alberca, M. Romero, J. Chaparro, Jerking stiff-man syndrome, J. Neurol. Neurosurg. Psychiatry 45 (1982) 1159–1160.

3]

R. Alberca, et al., Jerking stiff-man syndrome, J. Neurol. Neurosurg. Psychiatry 45 (1982) 1159–1160.

4]

H. Alexopoulos, S. Akrivou, M.C. Dalakas, Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders, Neurology 81 (2013) 1962–1964.

5]

Harry Alexopoulos, Sofia Akrivou, Goran Rakocevic, Marinos Dalakas, Serial CSF Studies of Anti-GAD Antibodies and GAD-IgG Intrathecal Synthesis in Stiff-Person Syndrome (SPS): Correlation with Disease Severity and Progression (P6.036), Neurology 90 (15 Supplement) (Apr 2018) P6.036.

6]

F. Ali, M. Rowley, B. Jayakrishnan, S. Teuber, M.E. Gershwin, I.R. Mackay, Stiff-person syndrome (SPS)and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies, JAutoimmun 37 (2011) 79–87, https://doi.org/10.1016/j.jaut.2011.05.005.

7]

E. Anagnostou, T. Zambelis, Botulinum toxin A in anti-GAD-positive stiff-limb syndrome, Muscle Nerve 46 (2012) 457–458.

8]

H. Arino, R. Hoftberger, N. Gresa-Arribas, et al., Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies, JAMA Neurol. 72 (8) (2015) 874–881.

9]

Helena Ariño, et al., Cerebellar Ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy, JAMA Neurol. 71 (8) (2014 August) 1009–1016.

10]

C. Armon, K.M. McEvoy, B.F. Westmoreland, P.G. McManis, Clinical neurophysiologic studies in stiff-man syndrome: use of simultaneous video-electro-encephalographic–surface electromyographic recording, Mayo Clin. Proc. 65 (7) (1990) 960–967.

11]

J.F. Baizabal-Carvallo, J. Jankovic, Stiff-person syndrome: insights into a complex autoimmune disorder, J. Neurol. Neurosurg. Psychiatry (December 2014), https:// doi.org/10.1136/jnnp-2014-309201 Published Online First: 15.

12]

B. Balint, S. Jarius, S. Nagel, et al., Progressive encephalomyelitis with rigidity and myoclonus: anew variant with DPPX antibodies, Neurology. 82 (17) (2014) 1521–1528 [[PubMed: 24696508]].

13]

R.A. Barker, T. Revesz, M. Thom, et al., Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressiveencephalomyelitis with rigidity, J. Neurol. Neurosurg. Psychiatry 65 (1998) 633–640.

14]

L. Baysal-Kirac, E. Tuzun, E. Erdag, C. Ulusoy, E.N. Vanli-Yavuz, E. Ekizoglu, S. Peach, M. Sezgin, N. Bebek, C. Gurses, A. Gokyigit, A. Vincent, B. Baykan, Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings, J. Neurol. 263 (2016) 455–466.

15]

Ö. Bektaş, L. Jacobson, H. Tutkak, S. Karagöl, B. Lang, L. Clover, A. Vincent, G. Deda, Epilepsy and autoimmunity in pediatric patients, Neuropediatrics 46 (2015) 13–19.

16]

A. Belbezier, et al., Multiplex family with GAD65-Abs neurologic syndromes, Neurol. Neuroimmunol. Neuroinflamm. 5 (1) (2017 Dec 5) e416.

17]

C. Berger, H.M. Meinck, Head retraction reflex in stiff-man syndrome and related disorders, MovDisord 18 (2003) 906–911.

18]

P. Blum, J. Jankovic, Stiff-person syndrome: an autoimmune disease, Mov. Disord. 6 (1991) 12–20.

19]

A. Boronat, J.M. Gelfand, N. Gresa-Arribas, et al., Encephalitis and antibodies to dipeptidylpeptidase-like protein-6, a subunit of Kv4.2 potassium channels, Ann. Neurol. 73 (1) (2013) 120–128 [[PubMed: 23225603]].

20]

L. Brosseau, N. Couroux, M. Marion, J. Theriault, L. Laferriere, Intra- and inter- rater reliability and factorial validity studies of the physiotherapy functional mobility profile (PFMP) in acute care patients, Physiother. Theory Pract. 15 (3) (1999) 147–154, https://doi.org/10.1080/095939899307694.

21]

T.M. Burns, H.R. Jones, L.H. Phillips, et al., Clinically disparate stiff-person syndrome with GAD65 autoantibody in a father and daughter, Neurology 61 (2003) 1291–1293.

22]

M.H. Butler, A. Hayashi, N. Ohkoshi, C. Villmann, C.M. Becker, G. Feng, P. De Camilli, M. Solimena, Autoimmunity to gephyrin in stiff-man syndrome, Neuron 26 (2000) 307–312.

23]

A.M. Campbell, H. Garland, Subacute myoclonic spinal neuronitis, J. Neurol. Neurosug. Psychiatry 19 (1956) 268–274.

24]

F. Cardoso, C. Eduardo, A.P. Silva, C.C. Mota, Chorea in fifty consecutive patients with rheumatic fever, Mov. Disord. 12 (1997) 701–703.

25]

A. Carvajal-González, M.I. Leite, P. Waters, M. Woodhall, E. Coutinho, B. Balint, B. Lang, P. Pettingill, A. Carr, U.M. Sheerin, R. Press, M.P. Lunn, M. Lim, P. Maddison, H.M. Meinck, W. Vandenberghe, A. Vincent, Glycine receptor antibodies in PERM and related syndromes:characteristics, clinical features and outcomes, Brain. 137 (2014) 2178–2192.

26]

Carmen Elena Cervantes, Hsien Lee Lau, Tina Ataian Binazir, Keith O. O'Brien, S.Cross Jonathan, Why it is not always anxiety: A tough diagnosis of Stiff person Syndrome, Case Rep. Neurol. Med. 2017 (2017) Article ID 7431092, 3 page.

27]

T. Chang, H. Alexopoulos, M. McMenamin, et al., Neuronal surface and glutamic acid decarboxylase autoantibodies in nonparaneoplastic stiff person syndrome, JAMA Neurol. 70 (9) (2013) 1140–1149.

28]

L. Cohen, Stiff-man syndrome. Two patients treated with diazepam, JAMA 195 (1966) 222–224.

29]

S.J. Crisp, B. Balint, A. Vincent, Redefining progressive encephalomyelitis with rigidity and myoclonus after the discovery of antibodies to glycine receptors, Curr. Opin. Neurol. 30 (3) (2017 Jun) 310–316.

30]

M. Cuturic, L.M. Harden, M.H. Kannaday, N.N. Campbell, R.K. Harding, Stiff-person syndrome presenting as eating disorder: a case report, Int. J. Eat. Disord. 44 (3) (2011) 284–286.

31]

P. De Camilli, A. Thomas, R. Cofiell, et al., The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-man syndrome with breast cancer, J. Exp. Med. 178 (1993) 2219–2223.

32]

L. Dahm, C. Ott, J. Steiner, et al., Seroprevalence of auto-antibodies against brain antigens in health and disease, Ann. Neurol. 76 (2014) 82–94.

33]

M. Dalakas, G. Rakocevic, J. Dambrosia, B.A. McElroy, Double-blind, placebo-controlled study of rituximab in patients with stiff-person syndrome (SPS), Ann. Neurol. 66 (2009) S21.

34]

M.C. Dalakas, G. Rakocevic, J.M. Dambrosia, H. Alexopoulos, B. McElroy, A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome, Ann. Neurol. 82 (2017) 271–277.

35]

M.C.Dalakas, Invited article: inhibition of B cell functions: implications for neurology, Neurology. 70 (23) (2008) 2252–2260 [[PubMed: 18519875]].

36]

M.C. Dalakas, M. Fujii, M. Li, B. McElroy, The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome, Neurology. 55 (10) (2000) 1531–1535.

37]

M.C. Dalakas, M. Fujii, M. Li, B. Lutfi, J. Kyhos, B. McElroy, High-dose intravenous immune globulin for stiff-person syndrome, N. Engl. J. Med. 345 (2001) 1870–1876.

38]

M.C. Dalakas, M. Fujii, M. Li, B. McElroy, The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome, Neurology 55 (10) (2000) 1531–1535.

39]

M.C. Dalakas, M. Fujii, M. Li, B. McElroy, The clinical spectrum of anti-GAD antibody-positivepatients with stiff-person syndrome, Neurology 55 (10) (2000) 1531–1535.

40]

M.C. Dalakas, M. Li, M. Fujii, D.M. Jacobowitz, Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies, Neurology 57 (2001) 780e4.

41]

M.C. Dalakas, Stiff person syndrome: advances in pathogenesis and therapeutic interventions, Curr. Treat. Options Neurol. 11 (2009) 102–110, https://doi.org/ 10.1007/s11940-009-0013-9.

42]

M.C. Dalakas, The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies, J. Neurol. 252 (Suppl. 1) (2005) I19–I25.

43]

M.C. Dalakas, W.M. Clark, Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record, Neurology. 60 (11) (2003) 1736–1737 [[PubMed: 12796522]].

44]

R.B. Darnell, J.B. Posner, Paraneoplastic syndromes involving the nervous system, N. Engl. J. Med. 349 (2003) 1543–1554.

45]

R.B. Darnell, Onconeural antigens and paraneoplastic neurologic disorders: at the intersection ofcancer, immunity, and the brain, Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4529–4536.

46]

D. Davis, B. Jabbari, Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A, Mov. Disord. 8 (1993) 371–373.

47]

Praveen Dayalu, W. James, Teene Stiff person Syndrome and other Anti-GAD–associated neurologic disorders, Semin. Neurol. 32 (2012) 544–549.

48]

B. De la Casa-Fages, F. Anaya, M. Gabriel-Ortemberg, F. Grandas, Treatment of stiff-person syndrome with chronic plasmapheresis, Mov. Disord. 28 (3) (2013) 396–397, https://doi.org/10.1002/mds.25167 [[PubMed: 23239368]].

49]

Aurélie Degeneffe, A case report of rigidity and recurrent lower limb myoclonus: progressive encephalomyelitis rigidity and myoclonus syndrome, a chameleon. Degeneffe et al, BMC Neurol. 18 (2018) 173.

50]

Eric Dinnerstein, et al., A patient with post-traumatic stress disorder developing Stiff person Syndrome is there a correlation? Cogn. Behav. Neurol. 20 (2007) 136–137.

51]

M. Dubey, et al., Neurological autoantibody prevalence in epilepsy of unknown etiology divyanshu, JAMA Neurol. 74 (4) (2017) 397–402.

52]

M.E. Duddy, M.R. Baker, Stiff person syndrome, Front Neurol. Neurosci. 29 (2009) 147–165.

53]

J.L. Dupond, L. Essalmi, H. Gil, et al., Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis, J. Clin. Neurosci. 17 (2010) 389–391.

54]

J.R. Economides, J.C. Horton, Eye movement abnormalities in stiff person syndrome, Neurology 65 (2005) 1462–1464.

55]

M. Elisak, D. Krysl, J. Hanzalova, K. Volna, C.G. Bien, F. Leypoldt, P. Marusic, The prevalence of neural antibodies in temporal lobe epilepsy and the clinical characteristics of seropositive patients, Seizure 63 (2018) 1–6.

56]

I. Elovaara, S. Apostolski, P. van Doorn, et al., EFNS guidelines for the use of intravenous immunglobulin in treatment of neurological diseases. EFNS task force on the use of intra venous immunglobulin in treatment of neurological disease, Eur. J. Neurol. 15 (9) (2008) 893–908.

57]

M.G. Erlander, N.J. Tillakaratne, S. Feldblum, et al., Two genes encode distinct glutamat edecarboxylases, Neuron 7 (1991) 91–100.

58]

L. Errichiello, G. Perruolo, A. Pascarella, P. Formisano, C. Minetti, S. Striano, Zara, P. Striano, Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: a study on 233 patients, J. Neuroimmunol. 211 (2009) 120–123.

59]

Alberto J. Espay, Robert Chen, Rigidity and spasms from autoimmune encephalomyelopathies: Stiff-Person syndrome, Muscle Nerve 34 (6) (2006) 677–690.

60]

Nathan E. Esplin, John W. Stelzer, Timothy B. Legare, Sayed K. Ali, Difficult to treat focal, stiff person syndrome of the left upper extremity, Case Rep. Neurol. Med. (2017) Article ID 2580620.

61]

M. Falip, L. Rodriguez-Bel, S. Castañer, J. Miro, S. Jaraba, J. Mora, J. Bas, M. Carreño, Musicogenic reflex seizures in epilepsy with glutamic acid decarbocylase antibodies, Acta Neurol. Scand. 137 (2018) 272–276.

62]

M. Falip, M. Carreño, J. Miró, A. Saiz, V. Villanueva, A. Quílez, A. Molins, I. Barceló, A. Sierra, F. Graus, Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies, Eur. J. Neurol. 19 (2012) 827–833.

63]

S.H. Fatemi, J.M. Stary, J.A. Earle, M. Araghi-Niknam, E. Eagan, GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum, Schizophr. Res. 72 (2005) 109–122.

64]

R. Fekete, J. Jankovic, Childhood stiff-person syndrome improved with rituximab, Case Rep. Neurol. 4 (2012) 92–96.

65]

M.K. Floeter, J. Valls-Solé, C. Toro, D. Jacobowitz, M. Hallett, Physiologic studies of spinal inhibitory circuits in patients with stiff-person syndrome, Neurology 51 (1998) 85–93.

66]

F. Folli, M. Solimena, R. Cofiell, et al., Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer, N. Engl. J. Med. 328 (1993) 546–551.

67]

J.J. Gagnier, G. Kienle, D.G. Altman, D. Moher, H. Sox, D. Riley, et al., The CARE guidelines: consensus basedclinical case reporting guideline development, Headache. 53 (10) (2013) 1541–1547, https://doi.org/10.1111/head.12246. [[PubMed: 24266334]].

68]

T.M. George, J.M. Burke, P.A. Sobotka, H.S. Greenberg, A.I. Vinik, Resolution of stiff-man syndrome with cortisol replacement in a patient with deficiencies of ACTH, growth hormone, and prolactin, N. Engl. J. Med. 310 (1984) 1511–1513.

69]

W. Gerschlager, P. Brown, Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome, Mov. Disord. 17 (3) (2002) 590–593 [[PubMed: 12112212]].

70]

O.S. Gershanik, Stiff-person syndrome, Parkinsonism Relat. Disord. 15 (2009) S130–S134.

71]

B. Giometto, D. Miotto, F. Faresin, V. Argentiero, T. Scaravilli, B. Tavolato, Anti-gabaergic neuronauto antibodies in a patient with stiff-man syndrome and ataxia, J. Neurol. Sci. 143 (1–2) (1996) 57–59.

72]

C.G. Goetz, H.L. Klawans, On the mechanism of sudden death in Moersch-Woltman syndrome, Neurology. 33 (7) (1983 Jul) 930–932.

73]

E.E. Gordon, D.M. Januszko, L. Kaufman, A critical survey of stiff-man syndrome, Am. J. Med. 42 (4) (1967 Apr) 582–599.

74]

F. Graus, Recommended diagnostic criteria for paraneoplastic neurological syndromes, J. Neurol. Neurosurg. Psychiatry 75 (2004) 1135–1140.

75]

S. Hadavi, A.J. Noyce, R.D. Leslie, Stiff person syndrome, Pract. Neurol. 11 (2011) 272–282.

76]

A.E. Harding, P.D. Thompson, R.S. Kocen, J.R. Batchelor, N. Davey, C.D. Marsden, Plasma exchange and immunosuppression in the stiff man syndrome, Lancet 2 (8668) (1989) 915 [[PubMed: 2571826]]Rakocevic and Floeter Page 18 Muscle Nerve. Author manuscript; available in PMC 2013 May 01. NIH-PAAuthor Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript.

77]

E. Hattan, M.R. Angle, C. Chalk, Unexpected benefit of propofol in stiff-person syndrome, Neurology. 70 (18) (2008) 1641–1642.

78]

Halassa M.M.P.G. Haydon, Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior, Annu. Rev. Physiol. 72 (2010) 335–355.

79]

P. Henningsen, H.M. Meinck, Specific phobia is a frequent non-motor feature in stiff mansyndrome, J. Neurol. Neurosurg. Psychiatry 74 (4) (2003) 462–465.

80]

W.F. Hickey, B.L. Hsu, H. Kimura, T-lymphocyte entry into the central nervous system, J. Neurosci. Res. 28 (1991) 254–260.

81]

Shannon R. Hinson, A. Sebastian Lopez-Chiriboga, James H. Bower, Joseph Y. Matsumoto, Anhar Hassan, Eati Basal, Vanda A. Lennon, Sean J. Pittock, Andrew McKeon, Glycine receptor modulating antibody predicting treatable stiff-personspectrum disorders, Neurol. Neuroimmunol. Neuroinflamm. 5 (March 2018) e438.

82]

T. Holmøy, G. Skorstad, K.M. Alvik, et al., Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord, Clin. Neurol. Neurosurg. 111 (2009) 708–712.

83]

J. Honnorat, A. Saiz, B. Giometto, et al., Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients, Arch. Neurol. 58 (2) (2001) 225–230.

84]

F.M. Howard Jr., A new and effective drug in the treatment of the stiff-man syndrome: preliminary report, Proc. Staff Meet. Mayo Clin. 38 (1963) 203–212.

85]

M. Hutchinson, P. Waters, J. McHugh, et al., Progressive encephalomyelitis, rigidity, andmyoclonus: a novel glycine receptor antibody, Neurology. 71 (16) (2008) 1291–1292 [[PubMed: 18852446]].

86]

P. Huy, *. Pham, Lance A. Williams III, Therapeutic plasma exchange in two patients with Stiff-person Syndrome, J. Clin. Apher. 31 (2016) 493–494.

87]

S.R. Irani, P. Pettingill, K.A. Kleopa, N. Schiza, P. Waters, C. Mazia, L. Zuliani, O. Watanabe, B. Lang, C. Buckley, A. Vincent, Morvan syndrome: clinical and serological observations in 29cases, Ann. Neurol. 72 (2012) 241–255.

88]

K. Ishizawa, T. Komori, K. Okayama, et al., Large motor neuron involvement in Stiff-man syndrome: a qualitative and quantitative study, Acta Neuropathol. 97 (1999) 63–70.

89]

Vincent Jachiet, et al., Acute respiratory failure in a patient with stiff-person syndrome, Neurocrit. Care. 25 (2016) 455–457.

90]

A. Jacob, M. Matiello, B.G. Weinshenker, D.M. Wingerchuk, C. Lucchinetti, Shuster, et al., Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients, Arch. Neurol. 66 (2009) 1128–1133.

91]

J. Jankovic, Immunologic treatment of Parkinson's disease, Immunotherapy. 10 (2018) 81–84.

92]

S. Jarius, O. Stich, J. Speck, Ch. Rasiah, B. Wildemann, H.M. Meinck, S. Rauer, Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis inpatients with stiff person syndrome, J. Neuroimmunol. 229 (1) (2010) 219–224 2010-12-15.

93]

E.W. Karlson, L. Sudarsky, E. Ruderman, S. Pierson, M. Scott, S.M. Helfgott, Treatment of stiff-man syndrome with intravenous immune globulin, Arthritis Rheum. 37 (1994) 915–918.

94]

F.P. Kendall, E.K. McCreary, P.G. Provance, M.M. Rodgers, W.A. Romani, Muscles: Testing and Function with Posture and Pain, Lippincott Williams & Wilkins, 2005.

95]

H. Khanlou, G. Eiger, Long-term remission of refractory stiff-man syndrome after treatment with intravenous immunoglobulin, Mayo Clin. Proc. 74 (12) (1999) 1231–1232 [[PubMed: 10593352]].

96]

S. Kono, H. Miyajima, M. Sugimoto, Y. Suzuki, Y. Takahashi, A. Hishida, Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titer, Intern. Med. 40 (9) (2001) 968–971.

97]

J. Kuchling, J. Shababi-Klein, A. Nümann, et al., GAD antibody-associated late-onset cerebellar ataxia in two female siblings, Case Rep. Neurol. 6 (2014) 264–270.

98]

W.F. Kuhn, P.J. Light, S.C. Kuhn, Stiff-man syndrome: case report, Acad. Emerg. Med. 2 (1995) 735–738.

99]

R. Kyskan, K. Chapman, A. Mattman, et al., Antiglycine receptor antibody and encephalomyelitis with rigidity and myoclonus (PERM) related to small cell lung cancer, BMJ Case Rep. (2013 Jun 21), https://doi.org/10.1136/bcr-2013-010027 2013:pii: bcr2013010027.

100]

S. La Spada, C. Negro, C. Nozzoli, V. De Marco, B. Passarella, Stiff person syndrome and motor mononeuropathy with conduction block: a singular association, Clin. Ter. 157 (2006) 237–239.

101]

D.S. Ledet, R. Handgretinger, T.E. Bertorini, G.A. Hale, R.C. Ribeiro, R.B. Khan, Leucoencephalopathy, transverse myelopathy, and peripheral neuropathy in association with glutamic acid decarboxylase-65 (GAD) antibodies in children with cancer, J. Child Neurol. 23 (2008) 1357–1362.

102]

P.N. Leigh, J.C. Rothwell, M. Traub, et al., A patient with reflex myoclonus and muscle rigidity:“jerking stiff-man syndrome”, J. Neurol. Neurosurg. Psychiatry 43 (1980) 1125–1131.

103]

L.M. Levy, M.C. Dalakas, M.K. Floeter, The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid, Ann. Intern. Med. 131 (1999) 522–530.

104]

D.A. Lewis, D.W. Volk, T. Hashimoto, Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction, Psychopharmacology 174 (2004) 143–150.

105]

S. Liimatainen, M. Peltola, L. Sabater, et al., Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy, Epilepsia 51 (5) (2010) 760–767.

106]

J.B. Lilleker, et al., Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications, Seizure (2014) 598–602.

107]

M.E. Lobo, M.L. Araújo, C.A. Tomaz, N. Allam, Stiff-person syndrome treated with rituximab, BMJ Case Rep. (2010), https://doi.org/10.1136/bcr.05.2010.3021 2010:pii: bcr0520103021; PubMed PMID: 22802263; PubMed Central PMCID: PMC3029087.

108]

P.J. Lorenzoni, R.H. Scola, C.S. Kay, H.A. Teive, L.H. dos Santos, L.C. Werneck, Electrophysiological characteristics in four patients from Brazil with stiff person syndrome, J. Clin. Neurosci. 19 (2012) 889–891.

109]

M.P. Malter, C. Helmstaedter, H. Urbach, A. Vincent, C.G. Bien, Anti-bodies to glutamic acid decarboxylase define a form of limbic encephalitis, Ann. Neurol. 67 (4) (2010) 470–478.

110]

Suvi Malter, C. Helmstaedter,, et al., Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy, Epilepsia (2010) 760–776.

111]

Michael P. Malter, et al., Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis, Ann. Neurol. (2010) 470–478.

112]

B. Mamoli, W.D. Heiss, E. Maida, I. Podreka, Electrophysiological studies on the “stiff-man” syndrome, J. Neurol. 217 (2) (1977) 111–121.

113]

B.V. Maramattom, Intrathecal baclofen pump implantation in a case of stiff person syndrome, Neurol. India 58 (2010) 115e7.

114]

P. Martinelli, P. Montagna, P. Pazzaglia, G. Coccagna, Electrophysiological findings in a case of stif fman syndrome associated with epilepsy and nocturnal myoclonus, Riv. Neurol. 48 (1978) 479–491.

115]

P. Martinelli, P. Pazzaglia, P. Montagna, G. Coccagna, Stiff-man syndrome associated withnocturnal myoclonus and epilepsy, J. Neurol. Neurosurg. Psychiatry 41 (5) (1978) 458–462.

116]

E. Martinez-Hernandez, H. Ariño, A. McKeon, et al., Clinical and immunologic investigations in patients with stiff-person spectrum disorder, JAMA Neurol. 73 (6) (2016) 714–720, https://doi.org/10.1001/jamaneurol.2016.0133.

117]

E. Martinez-Hernandez, M. Sepulveda, K. Rostasy, et al., Antibodies to aquaporin 4, myelinoligodendrocyte glycoprotein, and the glycine receptor alpha1 subunit in patients with isolated opticneuritis, JAMA Neurol. 72 (2015) 187–193.

118]

N. Mas, A. Saiz, M.I. Leite, et al., Antiglycine-receptor encephalomyelitis with rigidity, J. Neurol. Neurosurg. Psychiatry 82 (12) (2011) 1399–1401 [[PubMed: 21148607]].

119]

J.Y. Matsumoto, J.N. Caviness, K.M. McEvoy, The acoustic startle reflex in stiffman syndrome, Neurology. 44 (10) (1994) 1952–1955.

120]

McEvoy K, Stiff-man syndrome, Semin. Neurol. 11 (1991) 197–205.

121]

A. McKeon, E. Martinez-Hernandez, E. Lancaster, et al., Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype, JAMA Neurol. 70 (2013) 44–50.

122]

A. McKeon, M.T. Robinson, K.M. McEvoy, J.Y. Matsumoto, V.A. Lennon, J.E. Ahlskog, et al., Stiff-man syndrome and variants: clinical course, treatments, and outcomes, Arch. Neurol. 69 (2012) 230–238.

123]

A. McKeon, Stiff-man syndrome and variants clinical course, treatments, and outcomes, Arch. Neurol. 69 (2) (2012) 230–238.

124]

Andrew McKeon, et al., GAD65 neurological autoimmunity, Muscle Nerve 56 (2017) 15–27.

125]

B.C. McLeod, I. Sniecinski, D. Ciavarella, H. Owen, T.H. Price, M.J. Randels, J.W. Smith, Frequency of immediate adverse effects associated with therapeutic apheresis, Transfusion. 39 (1999) 282–288.

126]

R. Mehanna, J. Jankovic, Movement disorders in multiple sclerosis and other demyelinating diseases, J. Neurol. Sci. 328 (2013) 1–8.

127]

H.M. Meinck, K. Ricker, B. Conrad, The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine, J. Neurol. Neurosurg. Psychiatry 47 (1984) 280–287.

128]

H.M. Meinck, K. Ricker, P.J. Hülser, et al., Stiff man syndrome: neurophysiological findings in eightpatients, J. Neurol. 242 (1995) 134-142.

129]

H.M. Meinck, L. Faber, N. Morgenthaler, J. Seissler, S. Maile, M. Butler, M. Solimena, P. DeCamilli, W.A. Scherbaum, Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases, J. Neurol. Neurosurg. Psychiatry 71 (2001) 100–103.

130]

Hans-Michael Meinck, Philip D. Thomps, Stiff man syndrome and related conditions, Mov. Disord. 17 (5) (2002 Sep) 853–866.

131]

H.M. Meinck, Stiff man syndrome, CNS Drugs 15 (2001) 515–526.

132]

F. Miller, H. Korsvik, Baclofen in the treatment of stiff-man syndrome, Ann. Neurol. 9 (1981) 511–512.

133]

H. Mitsumoto, M.J. Schwartzman, M.L. Estes, et al., Sudden death and paroxysmal autonomic dysfunction in stiff-man syndrome, J. Neurol. 238 (1991) 91–96.

134]

F.P. Moersch, H.W. Woltman, Progressive fluctuating muscular rigidity and spasm (‘stiff-man'syndrome); report of a case and some observations in 13 other cases, Proc. Staff Meet. Mayo Clin. 31 (1956) 421–427.

135]

F.M. Molloy, M.C. Dalakas, M.K. Floeter, Increased brainstem excitability in stiff person syndrome, Neurology. 59 (3) (2002) 449–451.

136]

L.L. Morrisa, L. Dysch, P.M. Salkovskisa, N. Giffin, Reducing excess stiffness in Stiff person Syndrome using CBT: a case study, NeuroRehabilitation. 35 (2014) 627–631.

137]

B.B. Murinson, J.B. Guarnaccia, Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease, Neurology 71 (2008) 1955–1958, https://doi.org/10.1212/01.wnl.0000327342.58936.e0.

138]

B.B. Murinson, M. Rizzo, Improvement of stiff-person syndrome with tiagabine, Neurology 57 (2001) 366.

139]

K.M. Mäkelä, A. Hietaharju, A. Brander, J. Peltola, Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: the interplay between immunotherapy and anti-epileptic drugs. Front, Neurol. 9 (2018) 57.

140]

M.S. Nadal, A. Ozaita, Y. Amarillo, E. Vega-Saenz de Miera, Y. Ma, W. Mo, et al., The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K+ channels, Neuron. 37 (3) (2003) 449–461.

141]

S. Najjar, D. Pearlman, A. Najjar, V. Ghiasian, D. Zagzag, O. Devinsky, Extralimbic autoimmune encephalitis associated with glutamic acid decarboxylase antibodies: an underdiagnosed entity? EpilepsyBehav 21 (2011) 306–313.

142]

S. Nakane, K. Fujita, Y. Shibuta, et al., Successful treatment of stiff person syndrome with sequential use of tacrolimus, J. Neurol. Neurosurg. Psychiatry 84 (2013) 1177–1180.

143]

Nervenarzt, From stiff man syndrome to stiff person spectrum disorders, 89 (2) (2018 Feb) 207–218, https://doi.org/10.1007/s00115-017-0480-2.

144]

N. Niwa, J.M. Nerbonne, Molecular determinants of cardiac transient outward potassium current(I(to)) expression and regulation, J. Mol. Cell. Cardiol. 48 (1) (2010) 12–25.

145]

R. Ogilvie, H. Kolski, Adolescent stiff person syndrome: long term symptom remission on immunomodulatory therapy, Can. J. Neurol. Sci. (2019 May 24) 1–6, https://doi.org/10.1017/cjn.2019.74 Journal Canadien Des Sciences Neurologiques.

146]

B. Oskarsson, V. Pelak, D. Quan, et al., Stiff eyes in stiff-person syndrome, Neurology 71 (2008) 378–380.

147]

M.B. Pagano, B.B. Murinson, A.A. Tobian, K.E. King, Efficacy of therapeutic plasma exchange for treatment of stiff-person syndrome, Transfusion. 54 (7) (2014) 1851–1856.

148]

J. Palace, J. Newsom-Davis, B. Lecky, A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group, Neurology 50 (1998) 1778–1783.

149]

J. Peltola, P. Kulmala, J. Isojärvi, et al., Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy, Neurology. 55 (1) (2000) 46–50 [[PubMed: 10891904]].

150]

J. Peltola, P. Kulmala, J. Isojärvi, et al., Autoantibodies to glutamic acid decarboxylase in patientswith therapy-resistant epilepsy, Neurology 55 (1) (2000) 46–50.

151]

R.D. Penn, E.A. Mangieri, Stiff-man syndrome treated with intrathecal baclofen, Neurology 43 (1993) 2412.

152]

M. Petit-Pedrol, T. Armangue, X. Peng, et al., Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, andanalysis of the effects of antibodies, Lancet Neurol. 13 (3) (2014) 276–286 [[PubMed:24462240]].

153]

G. Piccolo, V. Cosi, C. Zandrini, A. Moglia, Steroid-responsive and dependent stiff-man syndrome: a clinical and electrophysiological study of two cases, Ital. J. Neurol. Sci. 9 (1988) 559–566.

154]

J. Piepgras, M. Holtje, K. Michel, Q. Li, C. Otto, C. Drenckhahn, et al., Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons, Neurology. 85 (10) (2015) 890–897.

155]

V. Pietrini, G. Pavesi, F. Andreetta, Miller fisher syndrome with positivity of anti-GAD antibodies, Clin. Neurol. Neurosurg. 115 (2013) 2399–2400.

156]

A. Piotrowicz, A. Thümen, M.I. Leite, et al., A case of glycine-receptor antibody-associate dencephalomyelitis with rigidity and myoclonus (PERM): clinical course, treatment and CSF findings, JNeurol 258 (2011) 2268–2270.

157]

C. Piovano, M. Piattelli, T. Spina, G. Iervese, G. Bosco, The stiff-person syndrome. Case report, Minerva Anestesiol. 68 (2002) 861–865.

158]

S.J. Pittock, C.F. Lucchinetti, J.E. Parisi, et al., Amphiphysin autoimmunity: paraneoplastic accompaniments, Ann. Neurol. 58 (2005) 96–107.

159]

M.Q. Poh, N.G. Simon, M.E. Buckland, et al., Evidence of T-cell mediated neuronal injury in stiff person syndrome with anti-amphiphysin antibodies, J. Neurol. Sci. 337 (2014) 235–237.

160]

K. Potter, Physical therapy during in-patient rehabilitation for a patient with Stiff-person Syndrome, J. Neurol. Phys. Ther. 30 (1) (2006) 28–38.

161]

Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome): report of a case and some observations in 13 other cases, Mayo Clin. Proc. 31 (1956) 421–427.

162]

A. Pugliese, M. Solimena, Z.L. Awdeh, C.A. Alper, T. Bugawan, H.A. Erlich, P. De Camilli, Eisenbarth GS: association of HLA-DQB1*0201 with stiff-man syndrome, J. Clin. Endocrinol. Metab. 77 (1993) 1550–1553.

163]

A. Qureshi, M. Hennessy, Stiff person syndrome (SPS) complicated by respiratory failure: successful treatment with rituximab, J. Neurol. 259 (2012) 180–181.

164]

R. Raju, G. Rakocevic, Z. Chen, G. Hoehn, C. Semino-Mora, W. Shi, R. Olsen, M.C. Dalakas, Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome, Brain. 129 (Pt 12) (2006) 3270–3276 [[PubMed: 16984900]].

165]

R. Raju, J. Foote, J.P. Banga, et al., Analysis of GAD65 autoantibodies in stiff-person syndrome patients, J. Immunol. 175 (2005) 7755–7762.

166]

Goran Rakocevic, Harry Alexopoulos, C. Marinos, Dalakas quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder, BMC Neurol. 19 (2019) 1.

167]

G. Rakocevic, R. Raju, C. Semino-Mora, M.C. Dalakas, Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies, Neurology. 67 (6) (2006) 1068–1070 [[PubMed: 17000981]].

168]

G. Rakocevic, R. Raju, M.C. Dalakas, Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity, Arch. Neurol. 61 (2004) 902–904.

169]

Goran Rakocevic, Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies, Neurology 67 (2006) 1068–1070.

170]

G. Rakocevic, et al., Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder, BMC Neurol. 19 (1) (2019 Jan 3) 1.

171]

M. Rizzi, R. Knoth, C.S. Hampe, P. Lorenz, M.L. Gougeon, B. Lemercier, et al., Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff person Syndrome, PLoS One 5 (2010) e10838.

172]

Simone Rossi, Monica Ulivelli, Maria Malentacchi, Giuseppe Greco, Sabina Bartalini, Patrizia Borgogni, Fabio Giannini, Effects of immunotherapy on motor cortex excitability in Stiff PersonSyndrome, J. Neurol. 257 (2010) 281–285.

173]

U. Rudolph, H. Mohler, GABA-based therapeutic approaches: GABAA receptor subtype functions, Curr. Opin. Pharmacol. 6 (2006) 18e23.

174]

A. Saiz, J. Arpa, A. Sagasta, et al., Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity, Neurology 49 (4) (1997) 1026–1030.

175]

A. Saiz, Y. Blanco, L. Sabater, et al., Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association, Brain 131 (2008) 2553–2563.

176]

F. Sandbrink, N.A. Syed, M. Dalakas, M. Hallett, M.K. Floeter, Increased motor cortex excitability in stiff person syndrome: a paired pulse TMS study, Electroencephalogr. Clin. Neurophysiol. 107 (1998) 90P–91P.

177]

Harini Sarva, Andres Deik, Aman Ullah1, William L. Severt, Clinical spectrum of stiff person syndrome: a review of recent reports, Tremor. Other. Hyperkinet Mov. (N Y). 6 (2016) 340.

178]

K. Schmierer, J.M. Valdueza, A. Bender, P. DeCamilli, C. David, M. Solimena, R. Zschenderlein, Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression, Neurology. 51 (1998) 250–252, https://doi.org/10.1212/WNL.51.1.250.

179]

G. Sechi, M. Barrocu, M.G. Piluzza, G.A. Cocco, G.A. Deiana, G.F. Sau, Levetiracetam in stiff-person syndrome, J. Neurol. 255 (2008) 1721–1725.

180]

R.J. Seitz, B. Blank, J.C. Kiwit, R. Benecke, Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofenadministration, J. Neurol. 242 (10) (1995) 618–622 [[PubMed: 8568521]].

181]

R. Shannon, et al., Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders, Neurol. Neuroimmunol. Neuroinflamm. March 5 (2018) e438.

182]

M.A. Sidransky, N.V. Tran, A.D. Kaye, Anesthesia considerations in stiff person syndrome, Middle East J. Anaesthesiol. 22 (2013) 217–221.

183]

P.L. Silbert, J.Y. Matsumoto, P.G. McManis, K.A. Stolp-Smith, B.A. Elliott, K.M. McEvoy, Intrathecal baclofen therapy in stiff-man syndrome: a double-blind, placebo-controlled trial, Neurology. 45 (10) (1995) 1893–1897 [[PubMed: 7477988]].

184]

G. Skorstad, A.L. Hestvik, F. Vartdal, et al., Cerebrospinal fluid T cell responses against glutamic acid decarboxylase 65 in patients with stiff person syndrome, J. Autoimmun. 32 (2009) 24–32.

185]

M. Solimena, F. Folli, R. Aparisi, G. Pozza, P. De Camilli, Autoantibodies to GABA-ergic neurons and pancreatic β cells in stiff-man syndrome, N. Engl. J. Med. 322 (22) (1990) 1555–1560 [[PubMed: 2135382]].

186]

M. Solimena, F. Folli, S. Denis-Donini, et al., Autoantibodies to glutamic acid decarboxylase in apatient with stiff-man syndrome, epilepsy, and type I diabetes mellitus, N. Engl. J. Med. 318 (16) (1988) 1012–1020.

187]

M. Solimena, F. Folli, Stiff-man syndrome and type I diabetes mellitus: a common autoimmune pathogenesis? Ann. Ist. Super. Sanita 24 (1988) 583–586.

188]

M. Solimena, P. De Camilli, Autoimmunity to glutamic acid decarboxylase (GAD) in stiff-man syndrome and insulin-dependent diabetes mellitus, Trends Neurosci. 14 (10) (1991) 452–457 [[PubMed: 1722364]].

189]

P. Somogyi, T. Klausberger, Defined types of cortical interneurone structure space and spike timing in the hippocampus, J. Physiol. 562 (2005) 9–26.

190]

R. Spehlmann, K. Norcross, S.C. Rasmus, N.L. Schlageter, Improvement of stiff-man syndrome with sodium valproate, Neurology 31 (1981) 1162–1163.

191]

C. Stayer, V. Tronnier, J. Dressnandt, et al., Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus, Neurology 49 (1997) 1591–1597.

192]

Stiff-man syndrome: clinical aspects and anti–islet cell antibodies as a disease marker, in: K.M. McEvoy, V.A. Lennon, R.B. Layzer, G. Sandrini, G. Piccolo, P. Martinelli (Eds.), Motor Unit Hyperactivity States, Raven Press, New York, NY, 1993, pp. 45–52.

193]

K. Stoeck, P.O. Carstens, S. Jarius, D. Raddatz, W. Stocker, B. Wildemann, et al., Prednisolone and azathioprine are effective in DPPX antibody-positive autoimmune encephalitis, Neurol. (R) Neuroimmunol. Neuroinflamm. 2 (3) (2015) e86.

194]

G.B. Stokin, M. Popovic, E. Gelpi, A. Kogoj, J. Dalmau, F. Graus, Neuropathologic features of anti dipeptidyl-peptidase-like protein-6 antibody encephalitis, Neurology. 84 (4) (2015) 430–432.

195]

W. Sun, J.K. Maffie, L. Lin, R.S. Petralia, B. Rudy, D.A. Hoffman, DPP6 establishes the A-type K(+) current gradient critical for the regulation of dendritic excitability in CA1 hippocampal neurons, Neuron. 71 (6) (2011) 1102–1115.

196]

A. Szűcs, Anti glutamate-decarboxylase antibodies: a liaison between localisation relatedepilepsy, stiff-person syndrome and type-1 diabetes mellitus, Ideggyogy Sz. 67 (7–8) (2014 Jul 30) 269–271.

197]

E.P. Sørgjerd, P.M. Thorsby, P.A. Torjesen, et al., Presence of anti-GAD in a non-diabetic population of adults; time dynamics and clinical influence: results from the HUNT study, BMJ Open Diabetes Res. Care 3 (2015) e000076.

198]

Masahito Takagi, et al., Cognitive dysfunction associated with anti-glutamic acid decarboxylase autoimmunity: a case-control study, BMC Neurol. 13 (2013) 76.

199]

A. Thümen, A. Moser, An uncommon paraneoplastic Ri-positive opsoclonus-myoclonus-like syndrome and stiff-person syndrome with elevated glutamate/ GABA ratio in the cerebrospinal fluidafter breast cancer, J. Neurol. 257 (2010) 1215–1217.

200]

J.A. Tinsley, E.M. Barth, J.L. Black, et al., Psychiatric consultations in stiff-man syndrome, J. Clin. Psychiatry 58 (1997) 444–449.

201]

W.O. Tobin, V.A. Lennon, L. Komorowski, C. Probst, S.L. Clardy, A.J. Aksamit, et al., DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients, Neurology. 83 (20) (2014) 1797–1803.

202]

H. Tohid, Anti-glutamic acid decarboxylase antibody positive neurological syndromes, Neurosciences 21 (3) (2016) 215–222.

203]

M.R. Turner, S.R. Irani, M.I. Leite, K. Nithi, A. Vincent, O. Ansorge, Progressive encephalomyelitis with rigidity and myoclonus, Neurology (Jul 2011), https://doi.org/10.1212/WNL.0b013e318227b176 WNL.0b013e318227b176.

204]

I. Ughratdar, G. Sivakumar, S. Basu, Spinal cord stimulation to abort painful spasms of atypical stiff limb syndrome, Stereotact. Funct. Neurosurg. 88 (2010) 183–186.

205]

L. Urak, M. Feucht, N. Fathi, K. Hornik, K. Fuchs, A GABRB3 promoter haplotype associated with childhood absence epilepsy impairs transcriptional activity, Hum. Mol. Genet. 15 (16) (2006) 2533–2541.

206]

Anandh Vaiyapuri, et al., Is Stiff person Syndrome benefited by physical therapy intervention? Summary of case reports, Biomed. Res. Int. (2019) 7. Article ID 5613680.

207]

O.M. Vasconcelos, M.C. Dalakas, Stiff-person Syndrome, Curr. Treat. Options Neurol. 5 (2003) 79–90.

208]

F.H. Vermeij, P.A. van Doorn, H.F. Busch, Improvement of stiff-man syndrome with vigabatrin, Lancet 348 (1996) 612.

209]

S. Vernino, B.P. O'Neill, R.S. Marks, J.R. O'Fallon, D.W. Kimmel, Immunomodulatory treatment trial for paraneoplastic neurological disorders, Neuro-oncol. 6 (1) (2004) 55–62.

210]

A.M. Vicari, F. Folli, G. Pozza, G.C. Comi, M. Comola, N. Canal, C. Besana, A. Borri, M. Tresoldi, M. Solimena, et al., Plasmapheresis in the treatment of stiff-man syndrome, N. Engl. J. Med. 320 (22) (1989) 1499.

211]

M.I. Vicente-Valor, P. Garcia-Llopis, L. Mejia Andujar, et al., Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report, J. Clin. Pharm. Ther. 38 (2013) 71–73.

212]

J.D. Warren, G. Scott, P.C. Blumbergs, et al., Pathological evidence of encephalomyelitis in the stiffman syndrome with anti-GAD antibodies, J. Clin. Neurosci. 9 (2002) 328–329.

213]

D.R. Weinberger, Anxiety at the frontier of molecular medicine, N. Engl. J. Med. 344 (2001) 1247–1249.

214]

U. Westblom, Stiff-man syndrome and clonazepam, JAMA. 237 (18) (1977) [[PubMed: 576704]].

215]

A.M. Whiteley, M. Swash, H. Urich, Progressive encephalomyelitis with rigidity, Brain 99 (1976) 27–42.

216]

J. Witherick, J.R. Highley, M. Hadjivassiliou, Pathological findings in a case of stiff person syndrome with anti-GAD antibodies, Mov. Disord. 26 (2011) 2138–2139.

217]

Z. Xiao, J. Shan, X. Huang, et al., Familial case reports of stiff-person syndrome, Clin. Neurophysiol. 126 (2015) 2408–2409.

218]

T. Yoshimoto, M. Doi, N. Fukai, et al., Type 1 diabetes mellitus and drug-resistant epilepsy:presence of high titer of anti-glutamic acid decarboxylase autoantibodies in serum and cerebrospinalfluid, Intern. Med. 44 (11) (2005) 1174–1177.

219]

C. Zhou, Z. Huang, L. Ding, M.E. Deel, F.M. Arain, C.R. Murray, et al., Altered cortical GABAA receptor composition, physiology, and endocytosis in a mouse model of a human genetic absence epilepsysyndrome, J. Biol. Chem. 288 (29) (2013) 21458–21472.